GLP-1 Market
LLY $1311.66 ▲ +3.2% NVO $39.63 ▲ +1.5% PFE $30.36 ▲ +1.7% VKTX $25.81 ▼ -2.2% KLRA $13.23 ▲ +2.4% GPCR $22.07 ▲ +0.3% RHHBY $59.11 ▼ -0.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

zovaglutide Arm 1

Company
Beijing QL Biopharmaceutical Co.,Ltd
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 22, 2026

Trial details
  • Completed NCT NCT05491421

    A Study of ZT002 in Healthy Participants

    Not yet reported QL Biopharmaceutical Australia Pty Ltd 32 participants Est. completion 2023-04-28 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06371326

    A Study of ZT002 Injection in Participants With Overweight or Obesity

    Not yet reported Beijing QL Biopharmaceutical Co.,Ltd 28 participants Est. completion 2024-10-17 1 site Stand-alone
    Other conditions: Overweight or Obesity
    View official trial listing →
  • Completed NCT NCT06423872

    A SAD Study of ZT002 Injection in Healthy Participants

    Not yet reported Beijing QL Biopharmaceutical Co.,Ltd 28 participants Est. completion 2023-12-08 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT07020884

    A Study of ZT002 Injection With Subjects With Overweight or Obesity

    Not yet reported Beijing QL Biopharmaceutical Co.,Ltd 303 participants Est. completion 2025-05-29 16 sites Stand-alone
    Other conditions: Overweight or Obesity
    View official trial listing →
  • Completed NCT NCT07065032

    A Study of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM)

    Not yet reported, Not yet reported Beijing QL Biopharmaceutical Co.,Ltd 27 participants Est. completion 2024-08-05 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT07230119

    A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)

    Not yet reported Beijing QL Biopharmaceutical Co.,Ltd 755 participants Est. completion 2027-06-26 45 sites Stand-alone
    Other conditions: Overweight , Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT07443059

    A Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy Participants

    Not yet reported Beijing QL Biopharmaceutical Co.,Ltd 40 participants Est. completion 2027-03-19 3 sites Stand-alone
    Other conditions: Overweight , Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT07550816

    Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants

    Not yet reported Beijing QL Biopharmaceutical Co.,Ltd 60 participants Est. completion 2027-03-26 1 site Stand-alone
    Other conditions: Overweight,Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT07697846

    A Study to Investigate the Effects of Zovaglutide (ZT002 Injection) on QTc Interval in Healthy Adults

    Not yet reported Beijing QL Biopharmaceutical Co.,Ltd 40 participants Est. completion 2027-03-24 1 site Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07812597

    A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)

    Not yet reported Beijing QL Biopharmaceutical Co.,Ltd 210 participants Est. completion 2028-03-24 16 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: zovaglutide Arm 1, ZT002, zovaglutide Arm 2, ZT002 injection, Zovaglutide

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.